清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Randomized trials of PSA screening

过度诊断 医学 随机对照试验 前列腺癌 内科学 指南 前列腺癌筛查 相对风险 前列腺特异性抗原 前列腺 妇科 肿瘤科 癌症 置信区间 病理
作者
Priya Dave,Sigrid Carlsson,Kara L. Watts
出处
期刊:Urologic Oncology-seminars and Original Investigations [Elsevier BV]
卷期号:43 (1): 23-28 被引量:11
标识
DOI:10.1016/j.urolonc.2024.05.014
摘要

The role of prostate-specific antigen (PSA) testing in prostate cancer (PCa) screening has evolved over recent decades with multiple randomized controlled trials (RCTs) spurring guideline changes. At present, controversy exists due to the indolent nature of many prostate cancers and associated risks of overdiagnosis and overtreatment. This review examines major RCTs evaluating PSA screening to inform clinical practices. We summarize findings from primary RCTs investigating PSA screening's impact on PCa mortality and incidence: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, the European Randomized Study of Screening for Prostate Cancer (ERSPC), and the Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP). The PLCO Trial randomized men to annual PSA and DRE screening or usual care, reporting no significant difference in PCa mortality between groups at 17 years (RR 0.93, [95% CI: 0.81-1.08]), yet significantly increased detection and concomitant decreased detection in Gleason 6 (RR 1.17, [95% CI: 1.11-1.23]) and 8-10 disease (RR 0.89, [95% CI: 0.80-0.99]) in the screening group, respectively. The ESPRC Trial randomized men across seven European countries to PSA screening every 2-4 years or usual care, noting a 20% reduction in PCa mortality at 9 years (RR 0.81, [95% CI: 0.65-0.98]) and significant decrease in metastatic disease at 12 years (RR 0.70, [95% CI: 0.60-0.82]). The CAP Trial assessed a single PSA screening test's impact on PCa mortality yielding no significant difference in PCa mortality at 10 years (RR 0.96, [95% CI: 0.85-1.08]). Limitations amongst studies included high contamination between study arms and low compliance with study protocols. While the CAP and initial PLCO trials showed no significant reduction in PCa mortality, the ERSPC demonstrated a 21% reduction at 13 years, with further benefits at extended follow-up. Differences in outcomes are attributed to variations in trial design, contamination, adherence rates, and PSA thresholds. Future studies are needed focus on optimizing screening intervals, targeting high-risk populations, and incorporating non-invasive diagnostic tools to improve screening efficacy and reduce associated harms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Xzx1995完成签到 ,获得积分10
刚刚
FashionBoy的应助被科研通管家采纳,获得10
3秒前
fairytaler的应助被科研通管家采纳,获得10
3秒前
现代的初之完成签到,获得积分10
9秒前
大模型的应助被蜗牛好好飞采纳,获得10
10秒前
ChatGPT完成签到,获得积分10
12秒前
慕青的应助被蜗牛好好飞采纳,获得10
16秒前
夏同学完成签到 ,获得积分10
17秒前
今后的应助被蜗牛好好飞采纳,获得10
22秒前
wwrjj完成签到,获得积分0
23秒前
搜集达人的应助被cc采纳,获得10
24秒前
大模型的应助被蜗牛好好飞采纳,获得10
27秒前
33秒前
33秒前
御坂10576号完成签到,获得积分10
33秒前
35秒前
义气的雅琴完成签到,获得积分10
36秒前
cc发布了新的文献求助10
38秒前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
39秒前
Harlotte完成签到 ,获得积分0
40秒前
蒋不惜完成签到,获得积分10
46秒前
changfox完成签到,获得积分10
46秒前
hyk完成签到 ,获得积分10
46秒前
milalala完成签到 ,获得积分10
56秒前
浚稚完成签到 ,获得积分10
56秒前
1分钟前
冷傲的夜白完成签到,获得积分10
1分钟前
岳晓燕完成签到 ,获得积分10
1分钟前
1分钟前
清脆代真发布了新的文献求助50
1分钟前
1分钟前
谭访冬完成签到,获得积分10
1分钟前
MUAN完成签到 ,获得积分10
1分钟前
1分钟前
细腻海瑶完成签到,获得积分10
1分钟前
铁瓜李完成签到 ,获得积分10
1分钟前
1分钟前
红烧肉耶完成签到 ,获得积分10
1分钟前
小小菜完成签到 ,获得积分10
1分钟前
雪山飞龙完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697